Abstract #3710

Ultra-high field MRI enables the in vivo quantification of the efficacy of candidate promyelinating molecules in the cuprizone mouse model

Isaac Mawusi Adanyeguh¹, Emilie Poirion¹, Daniel García-Lorenzo², Marie-Stephane Aigrot¹, Brahim Nait-Oumesmar¹, Boris Zalc¹, Alexandra Petiet^1,2, and Bruno Stankoff^1,3

¹Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Brain and Spine Institute, ICM, F-75013, Paris, France, Paris, France, ²Center for NeuroImaging Research (CENIR), Brain and Spine Institute, 75013 Paris, France, Paris, France, ³AP-HP, Saint Antoine Hospital, Department of Neurology, 184 bd Faubourg Saint Antoine, 75012 Paris, Paris, France

Endogenous remyelination can potentially restore rapid axonal-conduction and confer neuroprotection in chronic demyelinating diseases such as multiple sclerosis. We used T₂ mapping to evaluate the ability of two candidate pharmacological agents to promote remyelination in cuprizone-demyelinated mice. Demyelination was associated with increase in signal intensity and T₂ values in the corpus callosum and external capsules. T₂ values showed spontaneous recovery after discontinuation of cuprizone treatment, an effect accelerated following administration of the two compounds tested. This study confirms that in vivo MRI can be used to select pharmacological agents for their therapeutic potential on remyelination.

This abstract and the presentation materials are available to members only; a login is required.

Join Here